Antimicrobial Resistance (AMR), specifically the multidrug resistance (MDR), is the biggest public health threat of the era with projections for ~10 million deaths per year by 2050. Severe infections like nosocomial pneumonia, sepsis, and complicated urinary tract infections (cUTI) remain associated with significant morbidity and mortality. The AMR among many pathogens encountered in all types of infections has exploded over the last 2 decades. Although the organisms like Staphylococcus aureus mostly posed the threat of AMR traditionally, AMR in Gram-negative bacteria (GNB) like Enterobacterales spp. (e.g., Klebsiella pneumoniae, Escherichia coli), Pseudomonas aeruginosa, and Acinetobacter baumannii etc. has now supplanted Gram-positive pathogens.
Given the evolving burden of MDR infections, accelerated efforts are in place to emphasize the development of novel therapies. Recent clinical trials provide encouraging data about four novel agents (Tebipenem, Durlobactam-Sulbactam, Cefepime-Taniborbactam, and Xeruborbactam) in various phases of development. These agents have demonstrated a unique range of in-vitro activity against select MDR pathogens. While these are promising developments for future, as of now, diagnosing infections promptly using kits like Acutis Reveal™ covering these MDR pathogens to minimize the unintended/unnecessary use of antibiotics and treat appropriately at first, is the only measure to curb down the burden of AMR.
Comments